|
"lu sn"的相關文件
顯示項目 1-10 / 29 (共3頁)
1 2 3 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-08-06 |
Secular trends and survival impact of high proportion of curative treatments for hepatocellular carcinoma in Taiwan, 2011-2019
|
Kee, KM;Chen, CH;Liu, TW;Huang, YH;Hu, JT;Chau, GY;Chen, KH;Chiang, CJ;Lin, CC;Hung, CF;Wang, TE;Huang, SF;Ku, HY;Huang, BS;Ch'ang, HJ;Tseng, HP;Lu, SN |
| 國家衛生研究院 |
2022-12-31 |
Secular trends of clinical characteristics and survival of hepatocellular carcinoma in Taiwan from 2011 to 2019
|
Kee, KM;Chen, CH;Hu, JT;Huang, YH;Wang, TE;Chau, GY;Chen, KH;Chen, YL;Lin, CC;Hung, CF;Huang, SF;Liu, TW;Ku, HY;Huang, BS;Wang, YP;Tseng, HP;Chiang, CJ;Lu, SN |
| 國家衛生研究院 |
2022-01-14 |
Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B
|
Hu, HH;Jeng, WJ;Pan, MH;Luo, WS;Chang, CL;Huang, YT;Su, CY;Chiang, CT;Jen, CL;Chien, YC;Lu, SN;Wang, LY;Huang, LR;Lee, MH;Liu, J;Nguyen, MH;Chen, CJ;Yang, HI |
| 國家衛生研究院 |
2021-07-15 |
How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers?
|
Chen, MH;Lu, SN;Chen, CH;Lin, PC;Jiang, JK;D'Yachkova, Y;Lukanowski, M;Cheng, R;Chen, LT |
| 國家衛生研究院 |
2020-03 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, LT;Martinelli, E;Cheng, AL;Pentheroudakis, G;Qin, S;Bhattacharyya, GS;Ikeda, M;Lim, HY;Ho, GF;Choo, SP;Ren, Z;Malhotra, H;Ueno, M;Ryoo, BY;Kiang, TC;Tai, D;Vogel, A;Cervantes, A;Lu, SN;Yen, CJ;Huang, YH;Chen, SC;Hsu, C;Shen, YC;Tabernero, J;Yen, Y;Hsu, CH;Yoshino, T;Douillard, JY |
| 國家衛生研究院 |
2018-04-05 |
ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G;Qin, S;Ryoo, BY;Lu, SN;Yen, CJ;Feng, YH;Lim, HY;Izzo, F;Colombo, M;Sarker, D;Bolondi, L;Vaccaro, G;Harris, WP;Chen, Z;Hubner, RA;Meyer, T;Sun, W;Harding, JJ;Hollywood, EM;Ma, J;Wan, PJ;Ly, M;Bomalaski, J;Johnston, A;Lin, CC;Chao, Y;Chen, LT |
| 國家衛生研究院 |
2017-10 |
Serum soluble programmed cell death 1 level as a key predictor for spontaneous functional cure of chronic hepatitis B patients
|
Hu, HH;Pan, MH;Luo, WS;Chang, CL;Jeng, RWJ;Huang, YT;Su, CY;Chiang, CT;Jen, CL;Lu, SN;Wang, LY;Huang, LR;Shih, CH;Chen, CJ;Yang, HI |
| 國家衛生研究院 |
2016-05 |
Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa, GK;Qin, SK;Ryoo, BY;Lu, SN;Yen, CJ;Feng, YH;Lim, HY;Izzo, F;Colombo, M;Sarker, D;Bolondi, L;Vaccaro, GM;Harris, WP;Chen, ZD;Hubner, R;Meyer, T;Bomalaski, JS;Lin, CC;Chao, Y;Chen, LT |
| 中國醫藥大學 |
2014-03 |
A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse
|
(Lee CM);(Chen CY);(Chien RN);(Tseng KC);彭成元(Cheng-Yuan Peng);(Tung SY);(Fang YJ);(Huang YH);(Lu SN);(Hung CH);(Tsai TJ);(Fang CC);(Hsu CW);(Yeh CT)* |
| 中國醫藥大學 |
2013-03 |
Prediction models of long-term cirrhosis and HCC risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles
|
(Lee MH);楊懷壹(Hwai-I Yang);(Liu J);(Batrla-Utermann R);(Jen CL);(Iloeje UH);(Lu SN);(You SL);(Wang LY);(Chen CJ)* |
顯示項目 1-10 / 29 (共3頁)
1 2 3 > >>
每頁顯示[10|25|50]項目
|
